← Back to feed

Thalia Therapeutics plc

THAT · AIM · Health Care · mcap £11m today

All announcements

All RNS · 24 Key events · 15

30 Sep 26

Half-year Results

Strategic transformation establishes Thalia as a clinical-stage RNA therapeutics company with a diversified development pipeline
RNS 9797602 ↗
29 Sep 26

New Patent Granted for miRisten in China

Extends intellectual property protection for Thalia’s clinical-stage AML programme
RNS 9795929 ↗
25 Sep 26

RNA gene-silencing cardiovascular program advances

Thalia Therapeutics plc (AIM: THAT), a clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease, announces it has completed the initial chemistry synthesis of the...
RNS 9790260 ↗
15 Sep 26

Business Update and Notice of Results

Progress across clinical-stage oncology, cardiovascular and RNA delivery programmes
RNS 9771620 ↗
04 Aug 26

Holding(s) in Company
RNS 9703827 ↗
31 Jul 26

Total Voting Rights
RNS 9698567 ↗
29 Jul 26

Holding(s) in Company
RNS 9694380 ↗
23 Jul 26

Grant of Director Share Options

Thalia Therapeutics plc (AIM: THAT), a clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease, announces that it has granted options over a total of 200,000,000...
RNS 9684005 ↗
21 Jul 26

Holding(s) in Company
RNS 9680523 ↗
21 Jul 26

Holding(s) in Company
RNS 9680521 ↗
21 Jul 26

Holding(s) in Company
RNS 9679890 ↗
17 Jul 26

Result of AGM and Completion of Acquisition
RNS 9674971 ↗
17 Jul 26

AGM Statement

Thalia Therapeutics plc (AIM: THAT), a biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease, will hold its Annual General Meeting ("AGM") today at 11.00 a.m. at the offices of...
RNS 9673538 ↗
24 Jun 26

Posting of Annual Report and Notice of AGM
RNS 9635072 ↗
24 Jun 26

Acquisition and £2.75 million Fundraise

Acquisition of oncology company Sanmirna Therapeutics Inc for its clinical-stage Acute Myeloid Leukaemia RNA therapy
RNS 9633060 ↗
23 Jun 26

Final Results

Thalia Therapeutics plc (AIM: THAT), a biotechnology company developing innovative RNA-based therapeutics, in both oncology and cardiovascular disease, as well as broadly applicable delivery technologies, today announces its audited results for the year...
RNS 9632843 ↗
09 Jun 26

New article: RNA medicine enters its second act

New article: RNA medicine enters its second act
RNS 9607785 ↗
02 Jun 26

CEO Interview

CEO Interview: Building a Differentiated RNA Therapeutics Company
RNS 9597065 ↗
13 May 26

CEO Interview: Thalia’s RNA Therapeutics Strategy

Thalia Therapeutics plc (AIM: THAT), a biotech company developing innovative RNA therapeutics, is pleased to announce the release of a new video interview with Chief Executive Officer, Dr David Solomon.
RNS 9566512 ↗
20 Apr 26

Change of Registered Address

Thalia Therapeutics plc (AIM: THAT), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, announces that it has changed its registered address to 2 Portman Street, London, W1H...
RNS 9526916 ↗
17 Mar 26

Result of General Meeting and Change of Name
RNS 9478439 ↗
27 Feb 26

Notice of GM and Proposed Change of Name

Notice of General Meeting and Proposed Change of Name to Thalia Therapeutics plc
RNS 9449926 ↗
24 Feb 26

CEO Appointment & Name Change Thalia Therapeutics

CEO Appointment, Strategic Update and Name Change to Thalia Therapeutics
RNS 9443377 ↗
17 Dec 25

Business and Operational Update

N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to provide an operational update and business review.
RNS 9301600 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.